Flatiron Health partners with MUSC to assist oncology care clinicians
Flatiron Assist has over 700 oncologist users and has been leveraged in over 90k treatment decisions
Read more...Shares of Yahoo initially spiked, then ended the day down nearly 1% to $12.10, after news came out that Yahoo chose former Autodesk CEO Carol Bartz to become Chief Executiv of the struggling Internet giant.
Clearly, the market isn't that excited by the 60-year-old software executive. One analyst - Jeff Lindsay at Bernstein - wrote out his concerns:
"While we think Ms. Bartz has been a good CEO at Autodesk, a B2B software company, we question the logic of her selection... She is just keeping the seat warm until a deal is done with Microsoft. If so, we hope that a full acquisition of the business is being contemplated, and not just a search deal - because finding a strategy for Yahoo without search would likely be an even greater challenge for a new CEO.
If there is no impending deal with Microsoft, then we think Ms. Bartz is not a natural choice of CEO to restructure Yahoo and drive it towards a new strategic vision for three reasons: a) she has no consumer or advertising background - Yahoo makes most of its money in the deeply troubled display advertising sector b) she has no direct international management experience - the European and Asia-Pacific regions have not been key drivers of Yahoo's revenue growth as they have for competitors such as Google c) she has no obvious M&A experience - major Internet players like Google are completing one acquisition every 3-5 weeks."
Lindsay goes on to say that Bartz is "safe but generally uninspiring."
Ouch! Lindsay is harder on Bartz then I was on Terry Semel, when he became CEO of Yahoo years ago.
(Image source: CNet)
Founder and CEO of Vator, a media and research firm for entrepreneurs and investors; Managing Director of Vator Health Fund; Co-Founder of Invent Health; Author and award-winning journalist.
All author postsFlatiron Assist has over 700 oncologist users and has been leveraged in over 90k treatment decisions
Read more...While cancer rates increase, less than 10% of eligible patients participate in clinical studies
Read more...The company can automate tasks such as scheduling, confirmations, and triaging
Read more...